<DOC>
	<DOCNO>NCT00512096</DOCNO>
	<brief_summary>Primary Objective : -To evaluate feasibility efficacy multimodality treatment ( neoadjuvant chemotherapy prior extirpative surgery ) clinical stage TXN2-3M0 squamous cell carcinoma penis .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Patients With Squamous Cell Carcinoma Penis</brief_title>
	<detailed_description>Before treatment start , participant complete exam , include blood urine test . A CT scan abdomen pelvis do . Participants chest x-ray , bone scan , EKG ( heart test ) . A special heart function test may also need do participant . If necessary biopsy enlarge lymph node ( ) obtain prior treatment . Blood test repeat week treatment . CT scan abdomen pelvis Chest x-ray do 2 treatment Taxol , Ifosfamide , Cisplatin . These also do surgery . The drug Taxol , Ifosfamide Cisplatin give catheter ( plastic tube ) place vein arm collarbone . Taxol give 3 hour first day treatment cycle . To prevent allergic reaction , Taxol give , participant receive three drug . These Dexamethasone , Diphenhydramine , either Cimetidine Ranitidine . After Taxol , Ifosfamide give 2 hour every day first three day treatment cycle . To prevent possible irritation Ifosfamide bladder , participant also receive Mesna plastic catheter . Mesna give Ifosfamide every day . Mesna chemotherapy . It medication prevent side effect Ifosfamide bladder . Every day first three day cycle , Ifosfamide give , participant also receive Cisplatin catheter steady rate 2 hour , along Mannitol salt water flush kidney . This treatment give hospital require stay hospital 3-4 day . It repeat total 4 time ; every 21 day , participant high enough number white blood cell platelet . Participants may give injection G-CSF skin day 7 day ( day 6-12 cycle ) bring white cell faster chemotherapy . This also low risk severe infection . After complete 4 treatment chemotherapy , participant blood urine test , chest x-ray learn response tumor chemotherapy . They also CT scan abdomen pelvis . Participants response chemotherapy , show sign new spread cancer part body , surgery . Surgery do remove tumor . The lymph nod groin remove . The pelvic lymph node may also need remove . How much tissue remove depend far tumor spread . The surgeon explain specific surgery separate consent form . After completion treatment , physical exam , CT scan , chest x-ray , blood test , urine test do every 3 month 2 year . They do every 6 month . These procedure do physician M. D. Anderson participant 's doctor . If participant 's doctor , information need forward doctor M. D. Anderson . Participants expect come M. D. Anderson respective participate urologist/medical oncologist least every 6 month check-up . This investigational study . The FDA approve Taxol , Ifosfamide , Cisplatin , Mesna . Up 40 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Penile Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Written informed consent must obtain patient prior study entry . 2 . Age &gt; /= 14 year age . Life expectancy great equal 6 month . PS &lt; /= 2 ( ECOG ) . 3 . Patients histologically confirm squamous cell carcinoma penis present clinical stage ( T ( subscript ) xN ( subscript ) 23M ( subscript ) 0 ) disease base 19871992 TNM Staging System meet additional clinicopathologic criterion define protocol ( section 3.1 ) . 4 . Patients must adequate physiologic reserve evidence : absolute neutrophil count ( ANC ) &gt; /= 1,500/mm3 ( superscript ) platelet count &gt; /= 100,000/mm3 . Transaminases &lt; /= 2 time upper limit normal . Conjugated bilirubin &lt; /= 1.5mg/dL . Creatinine clearance ( either calculate measure ) &gt; /= 40ml/minute . 5 . No evidence active ischemia EKG , patient significant prior coronary artery disease history , ejection fraction 40 % . No evidence severe conduction abnormality EKG . 1 . Patients uncontrolled infection CNS disease . 2 . Distant metastasis ( TNM stage M1 , i.e. , lung , bone , visceral site , lymph node metastasis aortic bifurcation ) . 3 . Patients clinically negative inguinal examination palpable adenopathy meeting pathological clinical criterion ( i.e. , minimal nodal metastasis false positive inguinal examination ) . 4 . Prior systemic chemotherapy penile carcinoma . 5 . Prior radiation therapy inguinal pelvic lymph node .</criteria>
	<gender>Male</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Genitourinary</keyword>
	<keyword>Penile Cancer</keyword>
	<keyword>Neoadjuvant Chemotherapy</keyword>
	<keyword>Extirpative Surgery</keyword>
	<keyword>TanyN2-3M0 Squamous Cell Carcinoma Penis</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Platinol-AQ</keyword>
	<keyword>Platinol</keyword>
	<keyword>CDDP</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Ifex</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
</DOC>